Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000051 · ClinicalTrials.gov registry record · Phase 2
Eltrombopag for Post Transplant Thrombocytopenia
A Phase 2 study of Thrombocytopenia, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT01000051: Completed Phase 2 study of Thrombocytopenia, sponsored by M.D. Anderson Cancer Center.
NCT01000051 is a Phase 2 study of Thrombocytopenia that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 64 participants, below the 309-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01000051, a Phase 2 study of Thrombocytopenia, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study is to learn if eltrombopag can help to improve platelet counts in patients with low platelets after they have had a stem cell transplant. The safety of this drug will also be studied.
Primary Outcome
Comparison of the efficacy of eltrombopag and placebo in patients with thrombocytopenia post hematopoietic cell transplantation (HCT).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eltrombopag
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2010-02-17 |
| Est. Completion | 2018-04-04 |
| Phase | Phase 2 |
What the finished NCT01000051 record still lists
NCT01000051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 309-participant average among 20 other Thrombocytopenia trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Thrombocytopenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01000051 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01000051 about?
NCT01000051 is a clinical study titled "Eltrombopag for Post Transplant Thrombocytopenia". The goal of this clinical research study is to learn if eltrombopag can help to improve platelet counts in patients with low platelets after they have had a stem cell transplant. The safety of this drug will also be studied.
What is the current status of trial NCT01000051?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2010-02-17. Estimated completion is 2018-04-04.
What conditions does trial NCT01000051 study?
This clinical trial studies the following conditions: Thrombocytopenia.
What interventions are being tested in trial NCT01000051?
The interventions under investigation include: Placebo (DRUG), Eltrombopag (DRUG).
Who is sponsoring clinical trial NCT01000051?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01000051 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01000051's enrollment target sits among peer trials
64 7th of 20 higher than 14 of 20 other Thrombocytopenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thrombocytopenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia
RECRUITING · Phase 2
-
Luspatercept for Clonal Cytopenias of Uncertain Significance
RECRUITING · Phase 2
-
Using Romiplostim to Treat Low Platelet Counts During Chemotherapy in People With Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Receiving Tyrosine Kinase Therapy
COMPLETED · Phase 2
-
Daclizumab to Treat Chronic Immune Thrombocytopenia
COMPLETED · Phase 2
-
Complement Inhibition Using Eculizumab to Overcome Platelet Transfusion Refractoriness in Patients With Severe Thrombocytopenia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI